Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab maintenance and open-label extension study in ulcerative colitis
2023-506994-36-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 41
01
Overview
Phase 3, randomised, double-blind trial of risankizumab in autoimmune colitis (6 arms), sponsored by AbbVie Inc. Planned start Oct 2018; status: authorised.
02
Drugs
risankizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-506994-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506994-36-00.